3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
117
Unknown
20
Terminated
17
Recruiting
10
Active not recruiting
4
Not yet recruiting
3
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Squamous Cell Carcinoma of Head and Neck
14
Head and Neck Neoplasms
12
Lung Neoplasms
10
Uterine Cervical Neoplasms
9
Neoplasms
9
Cholangiocarcinoma
5
Carcinoma, Squamous Cell
5
Carcinoma
5
Mesothelioma, Malignant
4
Carcinoma, Hepatocellular
4
Tongue Neoplasms
3
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Laryngeal Neoplasms
3
Hypopharyngeal Neoplasms
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Neoplasms
2
Mesothelioma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Interventions
Oxaliplatin
4
Paclitaxel
3
Capecitabine
3
pembrolizumab
2
fludarabine
2
Trastuzumab
2
S 1 (combination)
2
Ramucirumab
2
Polymerase Chain Reaction
2
Irinotecan
2
Gastric Bypass
2
Fluorouracil
2
Cyclophosphamide
2
Biopsy
2
zimberelimab
1
tusamitamab ravtansine
1
talazoparib
1
relatlimab
1
olaparib
1
milademetan
1
atezolizumab
1
apatinib
1
XELOX
1
Valganciclovir
1
Taxes
1
Saline Solution
1
Nivolumab
1
Methods
1
Lubricant Eye Drops
1
Lidocaine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Stomach Neoplasms
×
Cisplatin
×
Clear all
NCT04859582
2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3
Withdrawn